Christopher R. Cline sold $3.1M of TVTX
CHIEF FINANCIAL OFFICER at Travere Therapeutics, Inc.. 50,508 shares at an average of $62.34, traded Sep 15, 2026, filed Sep 17, 2026.
Score components
- +22RoleCFO
- +25Trade size$3.1M at market
- +10Share of holdings soldSold 37% of holdings
- +15Cluster8 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001943192-26-000006, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 15, 2026 | MOption exercise Common Stock10b5-1 | +20,000 | $17.44 | $349k | 138,016 | 27 d ago |
| Sep 15, 2026 | SOpen-market sale Common Stock10b5-1 | -27,473 | $62.00 | $1.7M | 110,543 | 27 d ago |
| Sep 15, 2026 | SOpen-market sale Common Stock10b5-1 | -20,735 | $62.61 | $1.3M | 89,808 | 27 d ago |
| Sep 15, 2026 | SOpen-market sale Common Stock10b5-1 | -1,900 | $63.69 | $121k | 87,908 | 27 d ago |
| Sep 15, 2026 | SOpen-market sale Common Stock10b5-1 | -400 | $65.31 | $26k | 87,508 | 27 d ago |
| Sep 15, 2026 | MOption exercise Employee stock option (right to buy)derivative10b5-1 | -20,000 | $0.00 | $0 | 0 | 27 d ago |
Related signals
Other insiders at Travere Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | Travere Therapeutics, Inc. | Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER | $335k 5,375 shares | -11% | |
| 50Moderate | Travere Therapeutics, Inc. | Eric M Dube CHIEF EXECUTIVE OFFICER | $25M 400,000 shares | -76% | |
| 40Moderate | Travere Therapeutics, Inc. | Peter Heerma EVP, CHIEF COMMERCIAL OFFICER | $18M 283,189 shares | -129% | |
| 30Weak | Travere Therapeutics, Inc. | Jula Inrig EVP, Head of R&D & CMO | $2.8M 44,674 shares | -31% | |
| 30Weak | Travere Therapeutics, Inc. | Elizabeth E Reed Chief Legal Officer and GC | $2.3M 37,500 shares | -26% | |
| 40Moderate | Travere Therapeutics, Inc. | William E. Rote Chief Research Officer | $13M 209,048 shares | -108% | |
| 25Weak | Travere Therapeutics, Inc. | Jeffrey A Meckler director | $1.3M 20,000 shares | -18% | |
| 43Moderate | Travere Therapeutics, Inc. | Christopher R. Cline CHIEF FINANCIAL OFFICER | $43k 642 shares | -1% | |
| 5Weak | Travere Therapeutics, Inc. | Gary A Lyons director | $633k 10,000 shares | -15% | |
| 0Weak | Travere Therapeutics, Inc. | Roy D. Baynes director | $225k 4,500 shares | -10% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.